Associate Director
Monte Rosa Therapeutics
Associate Director
Monte Rosa Therapeutics
Develops targeted protein degraders for therapy
Monte Rosa Therapeutics is seeking a highly experienced Clinical Operations professional to lead the successful planning, implementation, and conduct of clinical trials across multiple indications. Reporting to the Head of Clinical Operations, the Associate Director, Clinical Operations will be responsible and accountable for development of operational program strategy and leading execution of First in Human through Phase III trials depending on program lifecycle, representing clinical operations on cross functional Core Teams, and managing clinical operations team members to ensure adherence with overall study timelines, budget, quality, and regulatory standards (ICH/GCP, internal SOPs). A genuine interest and understanding of the science supporting the MRT pipeline, an ability to work in a multidisciplinary team setting, and a commitment to developing new treatments for patients are critical for success.The candidate will have the ability to work Hybrid work arrangement with Boston office MRTx requires a 70% office presence..Availability for approximately 30–40% travel is required for site visits, co-monitoring, investigator meetings, and select international activities.
• Bachelor's degree in health sciences or related field. • Minimum of 10 years of global clinical trial and program operations experience with at least 4 years of independent clinical trial management through all phases of clinical trial execution (Start-up, maintenance, closeout). • Robust experience in oncology and or autoimmune and inflammatory diseases required. • Demonstrated experience with developing clinical operations strategy and plans including site monitoring, risk mitigation plans, recruitment plans, enrollment modeling and CRO/vendor oversight plans. • Experience with managing and demonstrating oversight of CROs, vendors and consultants• Extensive knowledge and application of current FDA Regulations, ICH/GCP guidelines in clinical trials. • Strong computer skills including knowledge of Excel, Word, PowerPoint, Outlook and MS Project/Smartsheet. • Outstanding ability to communicate in an open and clear manner, listening effectively and inviting response and discussion with internal partners and external service providers. • Ability to collaborate effectively with the study team, cross-functional team members and external partners (including investigator and site staff) using collaborative negotiation skills. • Proficient in risk management to prevent and overcome complex safety and compliance related issues during clinical program implementation. • Comfortable in a fast paced, results-driven, highly accountable environment with large potential impact. • 20% travel required.
Compensation: 175000 to 210000 (USD)
Develops targeted protein degraders for therapy
Monte Rosa Therapeutics develops molecular glue degraders (MGDs) to treat cancer and autoimmune/inflammatory diseases using its QuEEN discovery engine, a platform that fuses AI-guided chemistry, proteomics, and structural biology to design MGDs. MGDs work by bringing a target protein together with an E3 ligase, tagging the protein for destruction by the cell's proteasome rather than just inhibiting it. The company distinguishes itself with the QuEEN platform, partnerships with Roche and Novartis for joint development and funding, and a portfolio that includes MRT-2359, MRT-6160, and MRT-8102 as clinical-stage programs. Its goal is to discover, develop, and commercialize MGDs, grow its pipeline, and create value through collaborations, upfront payments, milestones, and royalties while delivering treatments for patients with serious diseases.
Explore more opportunities at Monte Rosa Therapeutics